Summary
WASHINGTON (AP) -- An antibiotic linked to rare reports of severe liver problems, including several deaths, will be subjected to new scrutiny by federal health advisers.
The Food and Drug Administration has asked a panel of outside experts to discuss the overall risks and benefits of the antibiotic Ketek during a Dec. 14-15 meeting, according to a federal notice released Tuesday.See the full content of this document
Extract
Antibiotic Faces an Fda Review
The announcement comes as the Senate Finance Committee investigates allegations of fraud connec...
See the full content of this document
Sponsored links
